Project Details
Description
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guerin (BCG) in Participants with BCG-naive High-Risk Non-Muscle Inv
Status | Active |
---|---|
Effective start/end date | 4/19/23 → 5/28/29 |
Funding
- JANSSEN RESEARCH & DEVELOPMENT, LLC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.